tbuckley/cabot-search huggingface dataset:
Remembering Patient Gender in Sexual Orientation–Based Research—Reply
Authors: Adele Levine, Brandyn D. Lau, Adil H. Haider
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71]
Authors: Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer
Journal: European Urology (2018)
Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: Final survival analysis of the German ADEBAR phase III study.
Authors: Wolfgang Janni, Nadia Harbeck, Harald Leo Sommer, Brigitte Kathrin Rack, Doris Augustin, Wolfgang Simon, Julia Kathrin Jueckstock, Arthur Wischnik, Katja Annecke, Klaus Friese, Marion Kiechle
Journal: Journal of Clinical Oncology (2012)

1081 Background: Based on meta-analytic evidence, taxane containing adjuvant chemotherapy has been established as standard treatment in breast cancer (BC). However, in the MA-21 study, adriamycin-cyclophosphamide, followed by paclitaxel was significantly inferior FEC 120 . We prospectively compared a sequential epirubicin-docetaxel chemotherapy regimen to FEC 120 . Methods: The ADEBAR study was a multicenter phase III trial (n=1502) to evaluate whether pts with &gt; 3 axillary lymph node metastases BC benefit from a sequential anthracycline-docetaxel regimen (E 90 C–D: 4 cycles epirubicin [E] 90 mg/m 2 plus cyclophosphamide [C] 600 mg/m 2 q21d followed by 4 cycles docetaxel [D] 100mg/m 2 q21d) compared to dose-intensive anthracycline-containing polychemotherapy (FE 120 C: 6 cycles E 60 mg/m² d 1+8, 5-FU 500mg/m² d 1+8 and C 75 mg/m² d 1-14, q4w). The observation time (median – 95%CI) was 49.5 (47.4 – 51.3) m. Results: Treatment was stopped prematurely in 3.7% of the pts in the E 90 C–D arm and in 8.0% in the FE 120 C arm due to toxicity (p=0.0009). Antibiotic treatment was given in 10.4% (E 90 C–D) vs. 19.7% (FE 120 C), G-CSF support in 39.2% vs 61.4 % and erythropoietin stimulation in 8.7% vs. 20.0%, respectively (p&lt;0.0001). Haematological toxicity (leucopenia, neutropenic fever, thrombocytopenia, anemia) was significantly higher in the FEC-arm. At the time of the current analysis, 369 events of recurrence, were observed: 166 events in the FE120C group and 193 in the E90C–D group. The unadjusted hazard ratio (HR) was 0.877 (95 percent confidence interval, 0.722 to 1.065; p=0.3819, log-rank test). Overall survival in the two groups was not significantly different: (131 deaths with FEC vs. 134 with E90C–D (HR 0.996, 0.783-1.267, p=0.9691). Subgroup analyses, stratifying for tumor size, lymph node involvement, hormone receptor and HER2-neu status showed no significant difference between the two arms. Conclusions: Different toxicity profiles given, hematological toxicity in the FE120C group was more severe than in the E90C–D. In contrast to AC-P in earlier studies, EC-Doc provides a feasible and effective option to FEC120.
The balancing act of the liver: tissue regeneration versus fibrosis
Authors: Lucía Cordero-Espinoza, Meritxell Huch
Journal: Journal of Clinical Investigation (2018)

Epithelial cell loss alters a tissue's optimal function and awakens evolutionarily adapted healing mechanisms to reestablish homeostasis. Although adult mammalian organs have a limited regeneration potential, the liver stands out as one remarkable exception. Following injury, the liver mounts a dynamic multicellular response wherein stromal cells are activated in situ and/or recruited from the bloodstream, the extracellular matrix (ECM) is remodeled, and epithelial cells expand to replenish their lost numbers. Chronic damage makes this response persistent instead of transient, tipping the system into an abnormal steady state known as fibrosis, in which ECM accumulates excessively and tissue function degenerates. Here we explore the cellular and molecular switches that balance hepatic regeneration and fibrosis, with a focus on uncovering avenues of disease modeling and therapeutic intervention.
Finland invites you: to this issue of <i>BJSM</i> and to Helsinki on 8–9 June 2018
Authors: Peter Halén, Karim M Khan
Journal: British Journal of Sports Medicine (2018)

Welcome to this issue of the  British Journal of Sports Medicine ( BJSM ) guest edited by the Finnish Sports Physiotherapy Association. Our 2018 sports PT conference will focus on the shoulder but this issue contains much more than that. Let’s start at home (for us).

We are proud of our elite athletes and it looks like their combination of genetics and environment leads to longer life but beware of the risk of knee arthritis following knee injuries ( see page 89 ). Do elite athletes return to play at a greater rate than journeymen and journeywomen? The PhD research of Courtney Chun Han Lai ( see page 128 ) seems to say yes! Keep 83% in mind as compared with the 55% that is often …
Valuable Insights Into Visual Neuroplasticity After Optic Neuritis
Authors: Ahmed T. Toosy
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Management strategies of academic pigmented lesion clinic directors in the United States
Authors: Kelly C. Nelson, Douglas Grossman, Caroline C. Kim, Suephy C. Chen, Clara N. Curiel-Lewandrowski, James M. Grichnik, John M. Kirkwood, Sancy A. Leachman, Ashfaq A. Marghoob, Susan M. Swetter, Suraj S. Venna, Michael E. Ming
Journal: Journal of the American Academy of Dermatology (2018)
Regulatory considerations for clinical pharmacology during development of antibody-drug conjugates.
Authors: Stacy Shifflett Shord, Sarah J Schrieber, Hong Zhao, Brian Booth, Nam Atiqur Rahman
Journal: Journal of Clinical Oncology (2015)

2569 Background: Antibody-drug conjugates (ADCs) provide unique challenges during clinical development, as these products are a heterogeneous mixture of a monoclonal antibody and a small molecule payload. As such, the current paradigm has been to conduct studies that characterize the clinical pharmacology of both the antibody and small molecule components of the ADC. We have compiled a database of ADCs approved and under development to assess the study designs and outcomes to guide future FDA regulatory recommendations on evaluation of the clinical pharmacology for ADCs. Methods: Investigational New Drug (IND) applications, Biologics License Applications (BLA), product labeling and published literature were reviewed to develop the database. A description of the indication, antibody target, payload, linker, clinical pharmacology studies and available study results were compiled and analyzed. Results: Approximately 50 ADCs are currently under development and two ADCs are approved (Adcetris, Kadcyla). The most common payloads are auristatins (~60%) and maytansinoids (~20%), and the most common linkers are cleavable (~90%). Three components (i.e., conjugate, total antibody, and payload) were characterized to describe the pharmacokinetics of Adcetris and Kadcyla. While both the Adcetris and Kadcyla labeling describes the potential for drug interactions, dedicated drug interaction studies were only conducted for Adcetris. Organ impairment studies for both Adcetris and Kadcyla suggest decreased tolerability in patients with varying degrees of hepatic or renal impairment. Conclusions: As most ADCs are in early clinical development, FDA recommendations for clinical pharmacology studies are still evolving. Currently available data suggest that the pharmacokinetics of at least two components (e.g., conjugate and payload) should be described and incorporated into population and exposure-response analyses. The potential for drug interactions should be addressed. Organ impairment studies should be conducted with a specific focus on the assessment of safety, as well as on pharmacokinetics.
Abstract 44: Uveitis As An Important Ocular Sign To Help Early Diagnosis In Kawasaki Disease
Authors: Young Mi Hong, Han Seul Choi, Hae Soon Kim, Sejung Sohn
Journal: Circulation (2015)

Purpose: Atypical or incomplete Kawasaki disease (KD) frequently leads to delay in diagnosis and treatment. Delayed diagnosis is associated with increased risk of coronary artery aneurysm. Anterior uveitis peaks about a week after the onset of fever. The purpose of this study was to assess the differences in laboratorial findings including echocardiographic measurements, clinical characteristics such as duration of fever and treatment responses between KD patients with and without uveitis. Materials and Methods: 106 KD patients were studied from January 2008 to June 2013. Study group (n=28, KD with uveitis) was compared with control group (n=78, KD without uveitis). Laboratory data were obtained from each patients including complete blood count (CBC), erythrocyte sedimentation rate (ESR), platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total protein, albumin, C-reactive protein (CRP), brain natriuretic peptide (BNP). Echocardiographic measurement and intravenous immunoglobulin responses were compared between two groups. Result: The incidence of uveitis was 26.4%. Neutrophil counts were higher in the uveitis group compared with the control group (64.3±15.8(х10 3 /mm 3 ) vs. 54.4±19.3 (х10 3 /mm 3 )). The age of patients was higher in the uveitis group compared with the control group (40.5±21.4 months vs. 33.4±29.3 months). ESR (43.3±27.2 mm/hr vs. 30.8±24.6 mm/hr) and CRP (8.1±6.1 mg/dL vs. 7.9±10.7mg/dL) were slightly increased in the uveitis group compared with the control group, but there was no significant difference between the two groups. Coronary artery diameter was slightly increased in the uveitis group but there was no significant difference between the two groups. There were no significant differences in duration of fever, BNP, coronary arterial complication and treatment responses between the two groups. Conclusion: Uveitis is the one of the important ocular signs to diagnose incomplete KD. It is significantly associated with the patient’s age and neutrophil count but not with the other laboratory measurements, coronary arterial complication or treatment responses.
Peach pollen sensitisation is highly prevalent in areas of great extension of peach tree cultivar
Authors: Laura Victorio Puche, Damian López-Sánchez, Natalia blanca-Lopez, Maria Luisa Somoza-Alvarez, Elisa Haroun Diaz, Araceli Diaz-perales, María Gabriela Canto, Miguel Blanca
Journal: Journal of Allergy and Clinical Immunology (2018)
Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring
Authors: Stephen Z. Levine, Arad Kodesh, Alexander Viktorin, Lauren Smith, Rudolf Uher, Abraham Reichenberg, Sven Sandin
Journal: JAMA Psychiatry (2018)

The association of maternal use of folic acid and multivitamin supplements before and during pregnancy with the risk of autism spectrum disorder (ASD) in offspring is unclear.To examine the associations between the use of maternal folic acid and multivitamin supplements before and during pregnancy and the risk of ASD in offspring.A case-control cohort study of 45 300 Israeli children born between January 1, 2003, and December 31, 2007, were followed up from birth to January 26, 2015, for the risk of ASD. The cases were all children diagnosed with ASD and the controls were a random sample of 33% of all live-born children.Maternal vitamin supplements were classified for folic acid (vitamin B9), multivitamin supplements (Anatomical Therapeutic Chemical A11 codes vitamins A, B, C, and D), and any combination thereof exposed in the intervals before and during pregnancy.The association between maternal vitamin supplementation and the risk of ASD in offspring was quantified with relative risks (RRs) and their 95% CIs fitting Cox proportional hazards regression models adjusted for confounders. Sensitivity analyses were performed to test the robustness of the results.Of the 45 300 children in the study (22 090 girls and 23 210 boys; mean [SD] age, 10.0 [1.4] years at the end of follow-up), 572 (1.3%) received a diagnosis of ASD. Maternal exposure to folic acid and/or multivitamin supplements before pregnancy was statistically significantly associated with a lower likelihood of ASD in the offspring compared with no exposure before pregnancy (RR, 0.39; 95% CI, 0.30-0.50; P < .001). Maternal exposure to folic acid and/or multivitamin supplements during pregnancy was statistically significantly associated with a lower likelihood of ASD in offspring compared with no exposure during pregnancy (RR, 0.27; 95% CI, 0.22-0.33; P < .001). Corresponding RRs were estimated for maternal exposure to folic acid before pregnancy (RR, 0.56; 95% CI, 0.42-0.74; P = .001), maternal exposure to folic acid during pregnancy (RR, 0.32; 95% CI, 0.26-0.41; P < .001), maternal exposure to multivitamin supplements before pregnancy (RR, 0.36; 95% CI, 0.24-0.52; P < .001), and maternal exposure to multivitamin supplements during pregnancy (RR, 0.35; 95% CI, 0.28-0.44; P < .001). The results generally remained statistically significant across sensitivity analyses.Maternal exposure to folic acid and multivitamin supplements before and during pregnancy is associated with a reduced risk of ASD in the offspring compared with the offspring of mothers without such exposure.
Clusterin and Survivin in normal islets and islet cell tumors of pancreas
Authors: Darshana N. Jhala, Nirag C. Jhala, Jennifer Jones, William E. Grizzle
Journal: Cancer Research (2005)

2147  Introduction: Clusterin (Apo J) is a heat shock protein that modulates cellular proliferation. Increased expression of clusterin has been noted in breast cancers and Non-Hodgkin’s lymphoma but has not been investigated in islet cell tumors of pancreas (ICT). A structurally unique inhibitor of apoptosis protein, survivin, is differentially expressed in islet cells and is also prominently expressed in most common human carcinomas. The literature, however, is sparse regarding expression of clusterin and survivin in normal pancreas and ICT. Objective: This report describes the pattern of expression for survivin and clusterin in normal islet cells as well as in the ICT. Design: Five cases of normal pancreas, and 14 cases of ICT and adjacent uninvolved pancreas were immunostained with survivin (Clone: N18, Santa Cruz Biotechnology Inc., Santa Cruz, CA) as well as α (clone: 7D1; Novocastra Inc., CA) and β (clone: b-5; Santa Cruz Biotechnology Inc., Santa Cruz, CA) chains of clusterin. In addition, islet cells were also immunohistochemically stained for glucagon, insulin, gastrin, somatostatin, somatostatin receptor, pancreatic polypeptide, neuron specific enolase, S-100, and Grimelius stain. They were reviewed under bright field microscopy. Normal islet cells were also double labeled with fluorescent dyes - red (clusterin α and β chains separately) and green (glucagon and insulin separately). This allowed fluorescent microscopy to see the co-localization of clusterin with the type of hormone producing cells noted on the bright field microscopy. All stains were independently reviewed by three pathologists. Results: The strongest staining for both clusterin chains was noted at the periphery of normal as well as uninvolved islet cells. The pattern of immunostaining in normal and uninvolved endocrine pancreas was consistent with clusterin staining most strongly in a subset of cells also staining for glucagon and somatostatin. Survivin was noted in 82% (12/ 15) of normal and adjacent normal islets and unlike clusterin it stained all cells of the islets. Clusterin and survivin were expressed in 6/14 (43%) and 11/14 (79%) ICT , respectively. Interestingly, all ICT staining for glucagon (glucagonoma) also stained with both chains of clusterin (3/3, 100%). Clusterin expression also paralleled staining associated with glucagon and in ICT. Furthermore, based on fluorescent staining, both chains of clusterin co-localized with 90% cells expressing glucagon. Similarly, 60% glucagon expressing cells demonstrated co-localization with both chains of clusterin. Clusterin expression did not show co-localization with insulin expressing cells. Conclusion: Clusterin localizes in glucagon secreting cells in normal as well as uninvolved endocrine pancreas. While survivin may play a role in development of islet cell tumors, clusterin is differentially expressed in islet cells and may play a role in pathogenesis of glucagonoma.
Sexual Intercourse Among High School Students — 29 States and United States Overall, 2005–2015
Authors: Kathleen A. Ethier, Laura Kann, Timothy McManus
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Early initiation of sexual activity is associated with having more sexual partners, not using condoms, sexually transmitted infection (STI), and pregnancy during adolescence (1,2). The majority of adolescents initiate sexual activity during high school, and the proportion of high school students who have ever had sexual intercourse increases by grade; black students are more likely to have ever had sexual intercourse than are white students (3). The proportion of high school students overall who had ever had sexual intercourse did not change significantly during 1995-2005 (53.1% to 46.8%) (Division of Adolescent and School Health, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, unpublished data). To assess whether changes have occurred in recent years in the proportion of high school students who have ever had sexual intercourse, CDC examined trends overall and by grade, race/ethnicity, and sex among U.S. high school students, using data from the 2005-2015 national Youth Risk Behavior Surveys (YRBSs) and data from 29 states* that conduct the YRBS and have weighted data. Nationwide, the proportion of high school students who had ever had sexual intercourse decreased significantly overall and among 9th and 10th grade students, non-Hispanic black (black) students in all grades, and Hispanic students in three grades. A similar pattern by grade was observed in nearly half the states (14), where the prevalence of ever having had sexual intercourse decreased only in 9th grade or only in 9th and 10th grades; nearly all other states saw decreases in some or all grades. The overall decrease in the prevalence of ever having had sexual intercourse during 2005-2015 is a positive change in sexual risk among adolescents (i.e., behaviors that place them at risk for human immunodeficiency virus, STI, or pregnancy) in the United States, an overall decrease that did not occur during the preceding 10 years. Further, decreases by grade and race/ethnicity represent positive changes among groups of students who have been determined in previous studies to be at higher risk for negative outcomes associated with early sexual initiation, such as greater numbers of partners, condom non-use, teen pregnancy, and STI (1-3). More work is needed to understand the reasons for these decreases and to ensure that they continue.
Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival
Authors: William C. Jackson, Krithika Suresh, Vasu Tumati, Steven G. Allen, Robert T. Dess, Simpa S. Salami, Arvin George, Samuel D. Kaffenberger, David C. Miller, Jason W.D. Hearn, Shruti Jolly, Rohit Mehra, Brent K. Hollenbeck, Ganesh S. Palapattu, Matthew Schipper, Felix Y. Feng, Todd M. Morgan, Neil B. Desai, Daniel E. Spratt
Journal: European Urology (2018)
A Pilot Study in Cancer Patients with Central Venous Catheter Associated Deep Vein Thrombosis in Upper Extremity Treated with Rivaroxaban (Catheter 2)
Authors: Gwynivere A Davies, Alejandro Lazo-Langner, Esteban Gandara, Vicky Tagalakis, Martha L Louzada, Roweena Corpuz, Michael J. Kovacs
Journal: Blood (2016)